Navidea says NAV4694 clinical study is done

01/15/2013 | AuntMinnie.com (free registration)

Navidea Biopharmaceuticals has announced the completion of a clinical trial of its NAV4694 radiopharmaceutical, a biomarker used to identify cerebral beta amyloid in potential Alzheimer's disease cases. Results of the study, which was intended to determine the safety and efficacy of the biomarker when used with PET imaging, will be presented at this year's SNMMI Annual Meeting. Researchers are planning for a Phase III study of the agent this year. Meanwhile, Navidea said it has also secured rights to two other beta amyloid PET imaging agents from AstraZeneca: AZD2184 and AZD2995.

View Full Article in:

AuntMinnie.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA